VIVUS

Specialty pharma -- wholly-owned subsidiary of Icahn Enterprises (via IEH Biopharma LLC) since its Chapter 11 emergence; formerly NASDAQ-listed as VVUS

Privately held: no public share price · United States

Assets

(2 total)
2Total Assets
1Approved
1Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Approved
Noradrenergic/anticonvulsant (combination)Small molecule
Obesity
Phase 3
CalcineurinSmall molecule
Pulmonary Arterial Hypertension

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
May 2028 (1)
Extended-release tacrolimus (VI-0106)Phase 3Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension (PAH), Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH) …
Est. primary completion 2028-05-31 · NCT07612657 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.